It's Tuesday July 15th.

Welcome to Mark Foolery.

I'm Chris Hill joining me in studio today.

All the way from Marfa, Texas,

from Motley Pool Special Ops, Tom Jacobs.

Good to see you, my friend.

The pleasure is all yours, Chris.

It is, it is.

You know, for those who don't know, maybe have never heard of Marfa, Texas.

It is right there on the, arguably like the Western most edge of the state.

So-

Western and Southern, we're about an hour from the border.

Well, we won't get into the border discussion just yet.

No, not yet, but I do want to add that I get checked every time I go back and forth to the airport.

Well, you know, we talk all the time about our colleague Jim Gillies and

our border patrol to the north just continues to let him in the country so he's he's

Canadian I'm Texan. We've got earnings to talk about from JP Morgan.

Plug power continues to mystify me. But let's start with Johnson and Johnson.

Second Court of Profits came in higher than expected,

strong sales of their new drug for hepatitis C.

Really seemed to be a big part of what's fueling this.

Obviously Johnson to Johnson a huge company with a lot of revenue streams, but the

...